Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. (Nasdaq: HALO) is a biopharmaceutical company that develops drug-delivery technologies and products for pharmaceutical and biotechnology companies and patients. Its ENHANZE platform uses recombinant human hyaluronidase to facilitate subcutaneous delivery of injected drugs and fluids;… From the company’s description.
Over the twelve months to Sep 30, 2026, Halozyme Therapeutics, Inc. reported revenue of $1.80B, up 45.0% from a year earlier, and net income of $485.42M. Its operating margin was 37.4%, and operations generated $898.27M in cash. In fiscal 2025, it reported revenue of $1.40B, up 37.6% from fiscal 2024, and net income of $316.89M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Halozyme Therapeutics, Inc. does
In the company’s own words
Halozyme Therapeutics, Inc. (Nasdaq: HALO) is a biopharmaceutical company that develops drug-delivery technologies and products for pharmaceutical and biotechnology companies and patients. Its ENHANZE platform uses recombinant human hyaluronidase to facilitate subcutaneous delivery of injected drugs and fluids; Halozyme licenses the technology to partners and earns fees, milestones, royalties and revenue from bulk enzyme sales. The company also develops Hypercon and Surf Bio technologies for highly concentrated drug formulations, and designs, manufactures and commercializes auto-injectors and drug-device combination products. Its proprietary marketed products include Hylenex, a hyaluronidase formulation, and XYOSTED, a testosterone injection delivered with an auto-injector. Partnered ENHANZE products include formulations marketed by Roche, Takeda, Janssen, Bristol Myers Squibb and argenx; Halozyme earns royalties on ten commercial products. Its device portfolio includes VIBEX and QuickShot auto-injectors. The company expanded its delivery-technology portfolio through the acquisition of Elektrofi, renamed Halozyme Hypercon, and the addition of Surf Bio. Its website is www.halozyme.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- SAN DIEGO, CA
- Fiscal year end
- December
- CIK
- 1159036
- SIC
- 2836
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Halozyme Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Halozyme Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Halozyme Therapeutics, Inc.’s bonds, as funds hold them
Funds report holding 4 issues of Halozyme Therapeutics, Inc.’s debt, $387.13M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 0.87%, maturing 2027 to 2032.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Halozyme Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Halozyme Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Halozyme Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”